肢端雀斑样黑色素瘤的预后因素与生存分析
该研究基于1987至2013年连续纳入的123例肢端雀斑样黑色素瘤(ALM)患者队列,分析患者、肿瘤及治疗变量对总生存和黑色素瘤特异性生存的影响。Cox回归显示Breslow厚度增加、溃疡形成及接受放疗、化疗和疫苗治疗与更差的黑色素瘤特异性生存相关;校正多变量后,Breslow厚度>2 mm和疾病范围与不良黑色素瘤特异性生存显著相关,而非白人族裔与生存无关。
要点
- Breslow厚度>2 mm和疾病范围是ALM黑色素瘤特异性生存的独立不良预后因素。
- 非白人族裔与总生存或黑色素瘤特异性生存无关。
- 接受放疗、化疗和疫苗治疗与更差的黑色素瘤特异性生存相关。
核心结论
- ALM的黑色素瘤特异性死亡与肿瘤厚度增加和就诊时更晚期阶段相关,而与种族/族裔无关。
研究设计与样本
- 连续队列研究,纳入1987年至2013年诊断的123例ALM患者,分析总生存和黑色素瘤特异性生存的预测因素。
主要发现
- 单变量Cox回归显示Breslow厚度增加、溃疡形成、接受放疗、化疗和疫苗治疗与更差的黑色素瘤特异性生存相关。
- 多变量模型校正患者、肿瘤和管理变量后,Breslow厚度>2 mm和疾病范围与不良黑色素瘤特异性生存显著相关。
- 非白人族裔与更差的总生存或黑色素瘤特异性生存无关。
关键数值与推荐
- Breslow厚度>2 mm与不良黑色素瘤特异性生存显著相关(多变量分析)。
- 疾病范围与不良黑色素瘤特异性生存显著相关(多变量分析)。
- 单变量分析中,Breslow厚度增加、溃疡形成、接受放疗、化疗和疫苗治疗与更差的黑色素瘤特异性生存相关。
临床怎么用
- 临床应关注ALM患者的肿瘤厚度和就诊时疾病范围以评估预后。
- 不应因种族/族裔差异而假设ALM生存更差,需考虑就诊时机和医疗可及性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acral lentiginous melanoma (ALM) is a rare melanoma subtype that disproportionately afflicts people of colour. ALMs have a worse prognosis than other melanoma subtypes; this has been attributed to aggressive biological behaviour, more advanced stage at presentation and possible disparities in access to health care. OBJECTIVES: To examine, using comprehensive patient data and long-term follow-up information in a well-characterized cohort, how patient, tumour and clinical management variables impact overall and melanoma-specific survival. METHODS: We characterized a consecutive cohort of 123 ALMs diagnosed from 1987 to 2013 and analysed predictors of overall and melanoma-specific survival for their association with survival. RESULTS: Univariate hazard ratios and 95% confidence intervals using Cox regression models showed that increased Breslow depth, presence of ulceration, receipt of radiation, chemo- and vaccine therapy were associated with worse melanoma-specific survival. Notably, nonwhite race/ethnicity was not associated with worse overall or melanoma-specific survival. Multivariate modelling adjusting for patient, tumour and management variables revealed Breslow depth > 2 mm and disease extent as significantly associated with poor melanoma-specific survival. CONCLUSIONS: Melanoma-specific mortality among patients with ALM is associated with increased tumour thickness and more advanced stage at presentation, but not with race/ethnicity. Advanced tumour features at presentation and access to care may account for less favourable survival outcomes reported among nonwhite patients.
引用
- Asgari MM, Shen L, Sokil MM, et al. Prognostic factors and survival in acral lentiginous melanoma. Br J Dermatol. 2017. PMID: 28432682. doi:10.1111/bjd.15600
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。